Background: The contribution of induction chemotherapy (IC) before preoperative chemoradiation for esophageal cancer (EC) is not known. We hypothesized that IC would increase the rate of pathologic complete response ( pathCR).
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer for all patients (54 deaths) was 45.62 months [95% confidence interval (CI), 27.63-NA], with median OS 45.62 months (95% CI 25.56-NA) in Arm A and 43.68 months (95% CI 27.63-NA) in Arm B (P = 0.69). The pathCR rate in Arm A was 13% (7 of 55) and 26% (14 of 54) in Arm B (two-sided Fisher's exact test, P = 0.094). Safety was similar in both arms.
Conclusions: These data suggest that IC produces non-significant increase in the pathCR rate and does not prolong OS. Further development of IC before chemoradiation may not be beneficial. Clinical trial no.: NCT 00525915 (www.clinicaltrials.gov). Key words: esophageal carcinoma, induction chemotherapy, chemoradiation, randomized trial, pathologic complete response, esophageal preservation introduction Esophageal cancer is a local-regional disease in ∼50% of newly diagnosed patients in the United States. If a patient can withstand surgery, then localized esophageal cancer (LEC) in North America is most frequently treated with chemoradiation followed by surgery [1, 2] . However, even after trimodality therapy, patient outcomes remain poor. It is known that ∼20% of patients' tumors are highly sensitive to chemoradiation and, in these patients; no residual cancer cells can be identified in the surgical specimen ( pathologic complete response, pathCR) [3] [4] [5] [6] . Some reports also suggest that the achievement of pathCR can be associated with better survival outcome [3] [4] [5] [6] . Therefore, achievement of pathCR may be desirable. Moreover, if one could increase the rate of pathCR, it could spur esophageal preservation strategies. We hypothesized that induction chemotherapy before chemoradiation would increase the pathCR rate, and in turn this might yield a survival benefit.
The efficacy of systemic therapy in patients with LEC has been debated. Two major randomized trials investigating systemic therapy before surgery have produced opposite results and recommendations, [7, 8] but the contribution of preoperative chemotherapy to LEC patients' outcomes has been modest at best. In one trial of patients with LEC, preoperative chemotherapy was compared with preoperative chemoradiation in a randomized fashion and, although the trial was terminated prematurely, chemoradiation appeared to have a nonsignificantly higher efficacy than chemotherapy [9] . Our group developed the strategy of induction chemotherapy before chemoradiation [10] and the current trial represents further development of this strategy. The addition of induction chemotherapy to preoperative chemoradiation in a randomized trial has not been reported. Here, we report a randomized phase II trial to compare induction chemotherapy followed by preoperative chemoradiation versus preoperative chemoradiation in trimodality-eligible patients with LEC. The primary end point was pathCR. The chemotherapy regimen used was specifically developed because of considerable interest in oxaliplatin at the time of conception.
patients and methods objectives
The primary objective of the trial was to compare the rates of pathCR in the two treatment arms. The secondary objectives were to compare overall survival (OS), R0 resection rate, and safety (including 30-day surgical mortality). All eligible and volunteering patients were randomized to one of the two treatment arms of the study. The randomization was conducted using an in-house web-based software program that dynamically balanced the two groups for histology, baseline stage, gender, race, and age. All treatments were carried out in the outpatient setting. Upon recovery from chemoradiation (that usually took 5-7 weeks), patients underwent preoperative staging and were evaluated for surgery. The type of surgery (minimally invasive esophagectomy, three-field approach, transhiatal, or transthoracic) was chosen at the discretion of the operating team. Other pre-surgery investigations were standard. Patients assigned to Arm B first received induction chemotherapy for up to 8 weeks, with each 4-week cycle consisting of oxaliplatin 100 mg/m 2 on days 1 and 15 and fluorouracil 2200 mg/m 2 over 48 h as infusion starting on days 1 and 15. This particular regimen was a modification of a colon regimen and agreed upon by the Sponsor. A maximum of two cycles (four doses) were administered. An imaging study [e.g. positron emission tomography (PET) when feasible] or endoscopic evaluation was carried out after one cycle. These studies were used to judge the response of the first induction cycle. Cycle 2 was administered if there was no evidence of cancer progression. Following induction chemotherapy, patients received the treatment as described in Arm A. Dose adjustment guidelines were implemented for induction chemotherapy and for chemotherapy during radiation therapy (not detailed due space limitations).
follow-up
Upon completion of all protocol treatment, patients were followed every 3 months for 1 year, then every 6 months for two additional years, and finally 
statistical methods
The dynamic randomization was implemented using the method of Pocock and Simon [11] . We compared each of three parameters between the two treatment arms: (i) probability of pathCR for patients who underwent surgery ( primary end point of the study), (ii), median pre-surgery time to failure, and (iii) probability of death within 30 days post surgery. Chemoradiation is designated as Arm A and chemotherapy followed by chemoradiation as Arm B. Bayesian methods [12] were used to compute the posterior probability Pr(θ A < θ B | data), where θ A and θ B denote the pathCR probabilities in the two arms. We also computed 2 × {1 − Pr(θ A < θ B | data)} = 2 × Pr(θ B θ<θ A | data) to obtain a Bayesian posterior criterion that may be considered comparable to the two-sided P-value of a frequentist test. [13] and its generalizations also were used to assess association between each patient characteristic, treatment arm, and each of the three primary outcomes. The Kaplan-Meier method [14] was used to estimate probability of OS and pre-surgery failure-free probability. The log-rank test [15] and Cox model [16] were used to evaluate treatment and patient covariate effects on (OS) and pre-surgery time to failure.
pathCR assessment
The designation of pathCR or various degree of residual disease was based on our previously published report [6] that has been validated [17] .
role of the sponsor
The Sponsor (Sanofi Oncology, Princeton, NJ) provided research funding and oxaliplatin for carrying out this research. The Sponsor also participated in the trial design but has had no access to the data and had no input into this manuscript.
results patient characteristics Figure 1 shows the CONSORT diagram with reasons for patients dropping out through treatment trajectory.
chemotherapy and chemoradiation complications
Grade 3 or 4 complication rates by treatment arm were low and there was no grade 5 toxic effect due to chemotherapy or chemoradiation. Except for fatigue (seven patients in Arm A and four in Arm B), none of the complications exceeded the rate of 5%. Because of the low rate of toxic effect, these data are not shown in detail.
type of surgery and complications
One of the major objectives was to estimate and compare the probability of 30-day surgery-related mortality. Fortunately, None of these complications differed significantly between the two treatment arms. The rate of treatment failure before surgery was not significant in the two arms (P = 1.0) and the median time to treatment failure (Arm A median was 163 days and Arm B median was not estimatable) was also not significant (P = 0.204).
pathologic complete response rate
Supplementary To also examine the pathCR rates by a Bayesian analysis, if we denote the probabilities of pathCR for arms A and B, by θ A and θ B , respectively, and assume θ A and θ B both follow a noninformative beta (0.3, 0.7) prior distribution, then Pr(θ A < θ B | data) = 0.96. This implies that, given the observed data, there was a 96% posterior probability that the proportion of pathCR in arm B was higher than Arm A. As this posterior probability is analogous to a one-sided frequentist test, we also compute the Bayesian criterion 2%{1 − Pr(θ A < θ B |data)} = 0.08, which is numerically close to (although qualitatively very different from) the frequentist two-sided P-value 0.094. A fitted Bayesian logistic regression model accounting for performance status also suggested that Arm B had a higher chance to produce pathCR. By the nature of this randomized strategy, surgery was delayed in patients assigned to Arm B by 8 weeks; however, we do not believe that this short delay would have altered the pathCR rate [18] .
DFS and OS
The DFS of pathCR patients was longer compared with those who did not achieve a pathCR (P = <0.044, log-rank test). There was no significant difference in OS by pathCR and non-pathCR within either treatment arm or when the two arms were combined (P = 0.445).
There was no difference in OS of patients in the two treatment arms (P = 0.69, log-rank test; supplementary Figure S1 , available at Annals of Oncology online). discussion LEC, although potentially curable, presents multiple challenges to patients and medical providers alike. Chemoradiation is 
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associated with considerable toxic effect and surgery leads to lifestyle changes that are highly unpleasant. Following chemoradiation, acheivement of pathCR is desirable because it can be associated with improved OS. Acheivement of a high rate of pathCR also could allow exploration of esophageal preservation strategies. A treatment resulting in a high rate of pathCR also may make the predictive models [19, 20] more relevant. To preserve the esophagus, we need a predctive model that has high specificity and reasonably high sensitivity. In this project, our focus was on the attempt to increase the rate of pathCR. We hypothesized that the use of additional induction chemotherapy could potentially increase the rate of pathCR by reducing the bulk of the tumor and potentially making the ensuing chemoradiation more effective. However, our data clearly show that, while Arm B improved the rate of pathCR, the difference was not significant by conventional statistical comparison and, importantly, the OS distributions in the two arms were virtually identical. The lack of meaningful difference in the pathCR is difficult to explain. Perhaps, this type of generic strategy is too naive for a cancer of the esophagus where each tumor is reported to have at least 50 unique genetic alterations [21] A much more prudent approach will be based on molecular biology of the disease.
As there was a marginally significant improvement in the pathCR rate, as assessed by both frequentist and by Bayesian methods, a natural question is whether a larger sample size (a larger multicenter randomized trial) would have yielded a significant difference and a clinically meaningful difference in the pathCR rate. To answer this question, we note that Arm A had a less than traditional rate of pathCR (traditional being ∼20%). This could imply that both arms (for whatever reasons including well-known patient heterogeneity/selection and possibly including an unknown or 'latent' trial effect) carried out suboptimally and, therefore, a larger trial might yield positive results (assuming that the control arm will continue to underperform). To address this question, we carried out two assumption-based comparisons using hypothetical data (Table 2 ). In the first hypothetical dataset, we assumed that we would see a similar pathCR rate difference (that is the empirical rate in Arm B is twice that in Arm A) in a study with double the number of patients evaluable for pathCR, i.e. 110 in Arm A and 108 in Arm B. In the second hypothetical dataset, we again doubled the sample sizes but assumed instead that Arm B will have a 50% increase in the pathCR rate compared Arm A. The results, summarized in Table 2 , show that these hypothetical pathCR datasets produce varying P values, if the best pathCR rate is 26% (or 22% for the ITT population). This suggests that, from a practical perspective, further development of this strategy may not worthwhile since one would not see a pathCR rate much higher than 26% from Arm B. Additionally, the virtually identifcal OS seen in the two arms also suggests that a larger trial is not likely to produce significant OS advantage for the induction chemotherapy strategy. Therefore, the data do not provide compelling evidence to motivate further development of the induction chemotherapy strategy in LEC patients who are eligible for preoperative chemoradiation. We acknowledge that this suggestion can be a subject of considerable further discussion. Similar results have been reported recently in patients with head and neck cancer [22] .
In a retrospective analysis of 169 patients with squamous cell carcinoma (all with clinical T4 lesions) who were treated with multiple strategies, Miyata et al. [23] claimed minor superiority of IC plus chemoradiation over chemoradiation; however, this analysis is riddled with shortcomings and no clear conclusions are possible.
In conclusion, our data demonstrate that the use of induction chemotherapy before chemoradiation may not meaningfully increase the rate of pathCR, almost certainly does not increase 30-day surgical mortality, does not prolong OS, does not increase the rate of surgical complications, and is associated with no significant increase in grade 3 or 4 toxic effects. Based on the results of this first randomized study addressing this strategy, we Each comparison is done using both a frequentist two-sided Fisher's exact test, computing a Bayesian posterior probability based on non-informative beta (0.30, 0.70) priors, and doubling that probability to obtain a criterion that may be considered comparable to a two-sided P-value. Row 1 uses the actual data, while rows 2 and 3 are based on hypothetical data. 
